Bifogade filer
Results from XVIVO’s clinical trial NIHP2019 for heart preservation presented at ISHLT in Prague
Kurs
+11,73%
Likviditet
66,8 MSEK
Prenumeration
Kalender
| Tid* | ||
| 2025-10-23 | 07:30 | Kvartalsrapport 2025-Q3 |
| 2025-07-11 | 07:30 | Kvartalsrapport 2025-Q2 |
| 2025-04-25 | N/A | Årsstämma |
| 2025-04-24 | 07:30 | Kvartalsrapport 2025-Q1 |
| 2025-01-28 | 07:30 | Bokslutskommuniké 2024 |
| 2024-10-24 | - | Kvartalsrapport 2024-Q3 |
| 2024-07-12 | - | Kvartalsrapport 2024-Q2 |
| 2024-04-26 | - | X-dag ordinarie utdelning XVIVO 0.00 SEK |
| 2024-04-25 | - | Årsstämma |
| 2024-04-24 | - | Kvartalsrapport 2024-Q1 |
| 2024-01-25 | - | Bokslutskommuniké 2023 |
| 2023-10-24 | - | Kvartalsrapport 2023-Q3 |
| 2023-07-13 | - | Kvartalsrapport 2023-Q2 |
| 2023-04-26 | - | X-dag ordinarie utdelning XVIVO 0.00 SEK |
| 2023-04-25 | - | Årsstämma |
| 2023-04-24 | - | Kvartalsrapport 2023-Q1 |
| 2023-01-26 | - | Bokslutskommuniké 2022 |
| 2022-10-27 | - | Kvartalsrapport 2022-Q3 |
| 2022-07-13 | - | Kvartalsrapport 2022-Q2 |
| 2022-04-27 | - | X-dag ordinarie utdelning XVIVO 0.00 SEK |
| 2022-04-26 | - | Årsstämma |
| 2022-04-25 | - | Kvartalsrapport 2022-Q1 |
| 2022-01-27 | - | Bokslutskommuniké 2021 |
| 2021-10-28 | - | Kvartalsrapport 2021-Q3 |
| 2021-07-13 | - | Kvartalsrapport 2021-Q2 |
| 2021-04-23 | - | X-dag ordinarie utdelning XVIVO 0.00 SEK |
| 2021-04-22 | - | Årsstämma |
| 2021-04-21 | - | Kvartalsrapport 2021-Q1 |
| 2021-01-28 | - | Bokslutskommuniké 2020 |
| 2020-10-23 | - | Kvartalsrapport 2020-Q3 |
| 2020-10-14 | - | Extra Bolagsstämma 2020 |
| 2020-07-10 | - | Kvartalsrapport 2020-Q2 |
| 2020-04-09 | - | Kvartalsrapport 2020-Q1 |
| 2020-04-01 | - | X-dag ordinarie utdelning XVIVO 0.00 SEK |
| 2020-03-31 | - | Årsstämma |
| 2020-01-30 | - | Bokslutskommuniké 2019 |
| 2019-10-24 | - | Kvartalsrapport 2019-Q3 |
| 2019-07-12 | - | Kvartalsrapport 2019-Q2 |
| 2019-04-26 | - | X-dag ordinarie utdelning XVIVO 0.00 SEK |
| 2019-04-25 | - | Årsstämma |
| 2019-04-24 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-08 | - | Bokslutskommuniké 2018 |
| 2018-10-26 | - | Kvartalsrapport 2018-Q3 |
| 2018-07-13 | - | Kvartalsrapport 2018-Q2 |
| 2018-04-30 | - | X-dag ordinarie utdelning XVIVO 0.00 SEK |
| 2018-04-27 | - | Årsstämma |
| 2018-04-26 | - | Kvartalsrapport 2018-Q1 |
| 2018-02-09 | - | Bokslutskommuniké 2017 |
| 2017-10-27 | - | Kvartalsrapport 2017-Q3 |
| 2017-07-14 | - | Kvartalsrapport 2017-Q2 |
| 2017-04-27 | - | X-dag ordinarie utdelning XVIVO 0.00 SEK |
| 2017-04-26 | - | Årsstämma |
| 2017-04-25 | - | Kvartalsrapport 2017-Q1 |
| 2017-04-10 | - | Extra Bolagsstämma 2017 |
| 2017-02-08 | - | Bokslutskommuniké 2016 |
| 2016-10-27 | - | Kvartalsrapport 2016-Q3 |
| 2016-07-15 | - | Kvartalsrapport 2016-Q2 |
| 2016-05-04 | - | X-dag ordinarie utdelning XVIVO 0.00 SEK |
| 2016-05-03 | - | Årsstämma |
| 2016-04-26 | - | Kvartalsrapport 2016-Q1 |
| 2016-02-04 | - | Bokslutskommuniké 2015 |
| 2015-10-23 | - | Kvartalsrapport 2015-Q3 |
| 2015-08-13 | - | Kvartalsrapport 2015-Q2 |
| 2015-04-24 | - | X-dag ordinarie utdelning XVIVO 0.00 SEK |
| 2015-04-23 | - | Årsstämma |
| 2015-04-22 | - | Kvartalsrapport 2015-Q1 |
| 2015-02-05 | - | Bokslutskommuniké 2014 |
| 2014-10-24 | - | Kvartalsrapport 2014-Q3 |
| 2014-10-24 | - | Analytiker möte 2014 |
| 2014-08-13 | - | Kvartalsrapport 2014-Q2 |
| 2014-04-30 | - | X-dag ordinarie utdelning XVIVO 0.00 SEK |
| 2014-04-29 | - | Årsstämma |
| 2014-04-23 | - | Kvartalsrapport 2014-Q1 |
| 2014-02-07 | - | Bokslutskommuniké 2013 |
| 2013-11-07 | - | Kvartalsrapport 2013-Q3 |
| 2013-11-07 | - | Analytiker möte 2013 |
| 2013-07-11 | - | Kvartalsrapport 2013-Q2 |
| 2013-05-08 | - | X-dag ordinarie utdelning XVIVO 0.00 SEK |
| 2013-05-07 | - | Årsstämma |
| 2013-04-19 | - | Kvartalsrapport 2013-Q1 |
| 2013-02-19 | - | Bokslutskommuniké 2012 |
| 2012-11-01 | - | Kvartalsrapport 2012-Q3 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Mid Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Today, at the 2024 International Society of Heart and Lung Transplantation meeting in Prague, Czech Republic, the results from XVIVO’s clinical trial, NIHP2019, in heart transplantation were presented.
The results showed that the primary endpoint, representing severe complications after heart transplantation, was registered in 18.8% of the subjects who received a donor heart preserved with the XVIVO Heart Assist Transport and in 30.1% of subjects in the control group who received a donor heart transported on ice, the current gold standard.
The rates of severe primary graft dysfunction (PGD) after heart transplantation were also lower for patients who received a donor heart preserved with the XVIVO Heart Assist Transport (11% compared to 28%).
"This trial represents a significant evolution in donor heart preservation," says Filip Rega, Professor of Cardiac Surgery and Transplantation at the University Hospitals Leuven, Belgium, and coordinating investigator of the trial. "Primary graft dysfunction is a feared complication after heart transplantation associated with serious morbidity and mortality. The study outcomes reveal an important and clinically relevant reduction in primary graft dysfunction for patients who were transplanted with a donor heart preserved using this novel technology."
"The NIHP2019 trial is the result of many years of hard work and collaboration, marking one of the greatest achievements in the history of XVIVO. It brings us one step closer to realizing our vision that nobody should die waiting for a new organ. Currently, only 30 percent of available donated hearts are utilized for transplantation - that needs to change. Our heart technology demonstrates XVIVO’s dedication as a research-driven and innovative company committed to changing the paradigm in heart preservation," says Christoffer Rosenblad, CEO of XVIVO.
The NIHP2019 trial is a randomized, controlled, open label, multicenter clinical investigation of the XVIVO Heart Assist Transport to collect the safety and performance data to support CE marking. The NIHP2019 trial enrolled 203 patients in 15 institutions across 8 European countries between November 2020 and May 2023.
In the US, XVIVO has obtained Investigational Device Exemption (IDE) approval by FDA for a heart preservation trial (PRESERVE) to collect the safety and effectiveness data required to support future PMA applications. Recruitment in the PRESERVE trial is ongoing.
April 11, 2024
Gothenburg
Christoffer Rosenblad, CEO
XVIVO Perfusion AB (publ)
For further information, please contact:
Christoffer Rosenblad, CEO, +46 73 519 21 59, e-mail: christoffer.rosenblad@xvivogroup.com
Kristoffer Nordström, CFO, +46 73 519 21 64, e-mail: kristoffer.nordstrom@xvivogroup.com
About Us
Founded in 1998, XVIVO is the only medical technology company dedicated to extending the life of all major organs - so transplant teams around the world can save more lives. Our solutions allow leading clinicians and researchers to push the boundaries of transplantation medicine. XVIVO is headquartered in Gothenburg, Sweden, and has offices and research sites on two continents. The company is listed on Nasdaq and has the ticker symbol XVIVO. More information can be found on the website www.xvivogroup.com.
This information is information that XVIVO Perfusion AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-04-11 10:10 CEST.